Adial Pharmaceuticals, Inc. (NASDAQ:ADIL) Short Interest Down 87.7% in February

Adial Pharmaceuticals, Inc. (NASDAQ:ADIL) was the target of a significant decline in short interest in February. As of February 13th, there was short interest totaling 33,643 shares, a decline of 87.7% from the January 29th total of 273,317 shares. Currently, 3.1% of the shares of the company are sold short. Based on an average trading volume of 78,805 shares, the short-interest ratio is presently 0.4 days. Based on an average trading volume of 78,805 shares, the short-interest ratio is presently 0.4 days. Currently, 3.1% of the shares of the company are sold short.

Analyst Upgrades and Downgrades

A number of equities research analysts recently commented on the stock. Weiss Ratings restated a “sell (e+)” rating on shares of Adial Pharmaceuticals in a research report on Wednesday, January 21st. UBS Group set a $8.00 price objective on Adial Pharmaceuticals in a research report on Wednesday, February 11th. One investment analyst has rated the stock with a Buy rating, one has assigned a Hold rating and one has assigned a Sell rating to the stock. According to MarketBeat, the company currently has a consensus rating of “Hold” and an average target price of $22.75.

Institutional Inflows and Outflows

A number of large investors have recently made changes to their positions in the business. Armistice Capital LLC acquired a new stake in shares of Adial Pharmaceuticals during the fourth quarter worth $562,000. Jane Street Group LLC increased its stake in Adial Pharmaceuticals by 887.3% in the fourth quarter. Jane Street Group LLC now owns 121,841 shares of the company’s stock valued at $27,000 after purchasing an additional 109,500 shares during the last quarter. Finally, Citadel Advisors LLC acquired a new position in Adial Pharmaceuticals in the third quarter valued at $51,000. Hedge funds and other institutional investors own 16.41% of the company’s stock.

Adial Pharmaceuticals Stock Performance

Shares of NASDAQ:ADIL remained flat at $2.44 during trading on Wednesday. 60,219 shares of the stock were exchanged, compared to its average volume of 39,021. The firm has a market cap of $2.71 million, a PE ratio of -0.13 and a beta of 1.26. The firm’s fifty day moving average is $4.91 and its two-hundred day moving average is $7.38. Adial Pharmaceuticals has a twelve month low of $2.27 and a twelve month high of $30.25.

Adial Pharmaceuticals Company Profile

Adial Pharmaceuticals, Inc, incorporated in Delaware and founded in 2003, is a clinical-stage specialty pharmaceutical company dedicated to the development of treatments for addiction disorders and central nervous system conditions. The company’s mission centers on creating novel modalities designed to enhance patient adherence and clinical outcomes, particularly in areas of high unmet medical need. Adial leverages sustained-release delivery technologies to address the challenges associated with oral medication regimens in addiction therapy.

The company’s lead product candidate, AD04, is a bioerodible subcutaneous implant engineered to deliver naltrexone continuously over a multi-month period for individuals with alcohol dependence.